A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer

Review Oncology

Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses

Hsiang Ying Lee et al.

Summary: Abiraterone and enzalutamide have different adverse effects on the cardiovascular system, with abiraterone increasing the risk of cardiac disorders and enzalutamide increasing the risk of hypertension.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Scoping reviews: reinforcing and advancing the methodology and application

Micah D. J. Peters et al.

Summary: Scoping reviews are a common method of evidence synthesis with increasing methodological guidance and resources available. Despite available guidance, some publications may not consider the available tools when using the term 'scoping review'. Ensuring adherence to up-to-date methodological guidance and reporting standards is crucial for improving the rigor of scoping reviews.

SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Urology & Nephrology

Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

Roberto Saldanha Jarimba et al.

Summary: This study retrospectively evaluated patients with castration-resistant prostate cancer treated with abiraterone or enzalutamide from 2016 to 2019. Results showed that enzalutamide had a higher biochemical response rate than abiraterone in mCRPC patients, and achieving a biochemical response was associated with lower risks of biochemical progression and death.

ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study

Eugene B. Cone et al.

Summary: Studies using pharmacovigilance database found higher odds of cardiac events for abiraterone compared to other drugs, while no signal was found for enzalutamide. Patients on GnRH agonists therapy also had increased risk of cardiac events.

ECLINICALMEDICINE (2021)

Add to Collection

Article Tropical Medicine